IMPROVEMENT IN PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 52-WEEK DATA FROM THE CELEST STUDY

Laurent Peyrin-Biroulet  1     Edouard Louis  2     Edward Loftus Jr  3     Wan-Ju Lee  4     Fabio Cataldi  4     Ana P. Lacerda  4     Subrata Ghosh  5    
1 Lorraine University,Nancy,France
2 University Hospital CHU of Liège,Liège,Belgium
3 Mayo Clinic College of Medicine,Rochester,United States
4 AbbVie Inc.,North Chicago,United States
5 University of Birmingham,Birmingham,United Kingdom

Conference
UEG Week 2018

Citation
United European Gastroenterology Journal 2018; 6 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing